Consensus expectations for Q1 2026 put revenue at $23.44 billion and EPS at $2.68, while the stock's current price of $238.46 sits slightly below the average analyst target of $247.00.
Investors are primarily focused on the Innovative Medicine segment's ability to maintain growth despite intensifying biosimilar competition for its top-selling immunology drug, Stelara. Strong performance in oncology assets like Darzalex and the scaling of the MedTech robotic surgery portfolio are expected to provide critical offsets to pharmaceutical headwinds. Additionally, analysts will be scrutinizing the impact of China's volume-based procurement (VBP) on MedTech margins and the clinical progression of the newly launched oral psoriasis pill, ICOTYDE.